Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma
Y Ohtani1, T Harada, Y Funasaka
1Division of Molecular Genetics, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Kobe, Japan.
Abstract:
Ectopic expression of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse melanocytes induces melanoma formation. Although requirement of mGluR1 for development of melanoma in the initial stage has been demonstrated, its role in melanoma growth in vivo remains unclear. In this study, we developed novel transgenic mice that conditionally express mGluR1 in melanocytes, using a tetracycline regulatory system. Pigmented lesions on the ears and tails of the transgenic mice began to appear 29 weeks after activation of the mGluR1 transgene, and the transgenic mice produced melanomas at a frequency of 100% 52 weeks after transgene activation. Subsequent inactivation of the mGluR1 transgene in melanoma-bearing mice inhibited melanoma growth with reduction of immunoreactivity to phosphorylated ERK1/2, whereas mice with persistent expression of mGluR1 developed larger melanoma burdens. mGluR1 expression is thus required not only for melanoma development but also for melanoma growth in vivo. These findings suggest that growth of melanoma can be inhibited in vivo by eliminating only one of the multiple genetic anomalies involved in tumorigenesis.
Insights
Metabotropic glutamate receptor subtype 1 (mGluR1) drives melanoma development and growth in mice. Inhibiting mGluR1 in existing melanomas effectively halts tumor progression, suggesting a targeted therapeutic approach.
Area of Science:
- Oncology
- Neuroscience
- Dermatology
Background:
- Metabotropic glutamate receptor subtype 1 (mGluR1) ectopic expression in melanocytes initiates melanoma.
- The role of mGluR1 in established melanoma growth in vivo is not fully understood.
Purpose of the Study:
- To investigate the role of mGluR1 in melanoma development and growth.
- To assess the therapeutic potential of inhibiting mGluR1 in vivo.
Main Methods:
- Development of novel transgenic mice with a tetracycline-inducible mGluR1 expression system in melanocytes.
- Monitoring melanoma formation and growth after transgene activation and inactivation.
- Analysis of phosphorylated ERK1/2 levels as a marker of pathway activity.
Main Results:
- Conditional mGluR1 expression induced melanoma in 100% of mice within 52 weeks.
- Inactivation of the mGluR1 transgene significantly inhibited melanoma growth.
- Persistent mGluR1 expression correlated with larger melanoma burdens and reduced phosphorylated ERK1/2.
- Reduced phosphorylated ERK1/2 immunoreactivity was observed upon mGluR1 inactivation.
Conclusions:
- mGluR1 is essential for both the initiation and progression of melanoma in vivo.
- Targeting mGluR1 offers a potential strategy for inhibiting melanoma growth, even in established tumors.
- Eliminating a single genetic anomaly, mGluR1, can impede melanoma growth, highlighting therapeutic vulnerability.
Related Concept Videos
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...